#389 An ASA a day keeps the Afib at bay?
CLINICAL QUESTION
How do ASA and direct oral anticoagulants compare in atrial fibrillation and bleeding risk?
BOTTOM LINE
For patients of any age with atrial fibrillation, apixaban is superior to ASA for the prevention of strokes or systemic embolisms (1.6% apixaban versus 3.7% ASA) with no increased risk of intra-cranial hemorrhage or major bleeding. Other direct oral anticoagulants have not been studied in this context.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- Results statistically different unless
- In atrial fibrillation,1 only one Randomized Controlled Trial (RCT) comparing direct oral anticoagulants (apixaban) to ASA. 5599 participants with atrial fibrillation unsuitable for warfarin (example: labile INR), age~70, CHADS~2. After ~1.1 years:
- Stroke/systemic embolism: 1.6% (apixaban) versus 3.7% (ASA).
- <65 years old: 0.7% versus 2% (ASA), Number Needed to Treat (NNT)=77.
- >75 years old: 2% versus 6.1% (ASA), NNT=25.
- >85 years old: 1% versus 7.5% (ASA). NNT=16.2
- Major bleeding: 1.4% versus 1.2% (ASA), not statistically different.
- No significant differences in any age subgroup (including >85) between apixaban and ASA, but risk increases with age, example (apixaban): 0.7% <65 years-old versus 4.7% >85 years-old.1,2
- Intracranial hemorrhage or gastrointestinal bleeding, no differences (0.4% all groups).
- Stroke/systemic embolism: 1.6% (apixaban) versus 3.7% (ASA).
- Bleeding risks, various populations (example: embolic strokes of undetermined source). One systematic review of direct oral anticoagulants versus ASA. After ~17.2 months:3
- Apixaban (4 RCTS, 10,978 patients):
- Symptomatic intracranial hemorrhage (0.5% versus 0.8% ASA), not different.
- Major hemorrhage (2.8% versus 2.4% ASA), not different.
- Dabigatran (2 RCTs, 5,695 patients):
- Symptomatic intracranial hemorrhage (1.2% versus 1.2% ASA), not different.
- Major hemorrhage (2.7% versus 2.3% ASA), not different.
- Rivaroxaban (3 RCTs, 28,821 patients):
- Symptomatic intracranial hemorrhage (0.4% versus 0.2% ASA), Number Needed to Harm (NNH)=500.
- Major hemorrhage (2.2% versus 1.4% ASA), NNH=125.
- Apixaban (4 RCTS, 10,978 patients):
- Limitations: Few RCTs in frail patients, different populations, limited information regarding types of bleeding events.
CONTEXT
- 2020 Canadian Cardiovascular Society Guidelines:4
- Oral anti-coagulation: >65 years-old/history of stroke, hypertension, heart failure, diabetes.
- Otherwise: No antithrombotic unless recommended for secondary prevention coronary/peripheral artery disease.
- Apixaban, edoxaban superior to warfarin for prevention stroke/systemic embolism, less major bleeding events.5,6
Latest Tools for Practice
#403 A Whiff of Prevention: Treating Male Partners to Reduce Bacterial Vaginosis Recurrence
Does treating male sexual partners of females undergoing treatment for bacterial vaginosis infection decrease recurrence?
#402 Nipple Confusion or Nonsense? Pacifiers and Breastfeeding Duration
In term infants, does restricting early use of pacifiers result in higher rates of breastfeeding up to 6 months of age?
#401 Vape Expectations: Are electronic cigarettes the real deal for smoking cessation? (Update)
Are nicotine-containing e-cigarettes more effective than other available options for smoking cessation?
No antithrombotic unless recommended for secondary prevention coronary/peripheral artery disease
DOAC better than Warfarin for prevention of stroke/embolism
Confirmation
DOACs have less bleeding events than warfarin
confirmation
nice
nice explanation
Confirms my practice of using Apixaban over ASA
If a major drop in Hb to 83 from about 110 and negative endoscopy for source should you stop Apixaban completely?
Reassuring
GOOD TO KNOW
NEW INFORMATION
Good summary.
Apaxiban is the safest and most effective.
informative
no significant difference between apixaban and ASA wrt bleeding risks, nice to learn
apixaban better wrt stroke prevention
ASA not as effective
Apixiban better than ASA without increased bleeding risks.
I agree that apixiban is superior to ASA in stroke prevention
good information for young patients with Afib.